Related Experiment Video
Updated: Jun 25, 2026
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Acute Lung Functional and Airway Remodeling Effects of an Inhaled Highly Selective Phosphodiesterase 4 Inhibitor in
Matthias Christian Hütten1,2, Tim Brokken1,2, Helene Widowski1,2,3
1Neonatology, Pediatrics Department, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
Insights
High doses of inhaled PDE4 inhibitors can harm premature lungs, impairing oxygenation and lung development. Low doses offer only modest benefits, indicating a narrow therapeutic window for treating neonatal lung injury.
Area of Science:
- Neonatal medicine
- Pulmonology
- Pharmacology
Background:
- Phosphodiesterase (PDE) inhibition is explored for neonatal lung injury treatment.
- Inhaled PDE4 inhibitors like GSK256066 may impact premature lung development.
- Previous studies suggest potential detrimental effects of PDE4 inhibition in preterm lungs.
Purpose of the Study:
- To investigate the dose-dependent effects of inhaled GSK256066 on lung function, structure, and alveolar development in a preterm lamb model.
- To assess the impact of low and high doses of an inhaled PDE4 inhibitor on mechanical ventilation outcomes.
- To determine the therapeutic window for PDE4 inhibitors in the context of neonatal lung injury.
Main Methods:
- Utilized a triple-hit lamb model simulating Ureaplasma-induced chorioamnionitis, prematurity, and mechanical ventilation.
- Administered inhaled GSK256066 at low (iPDE1) and high (iPDE10) doses to ventilated preterm lambs.
- Compared outcomes with unventilated (NOVENT) and ventilated control (Control) groups.
Main Results:
- High-dose GSK256066 impaired oxygenation during mechanical ventilation.
- Alveolar development, specifically the budding of secondary septae, appeared reduced in the high-dose group, suggesting impaired alveologenesis.
- Low-dose GSK256066 provided only modest improvements in ventilation-induced lung injury.
Conclusions:
- Inhaled PDE4 inhibitors have a narrow therapeutic window in the developing preterm lung.
- High doses of GSK256066 can be detrimental, exacerbating lung injury and hindering development.
- Further research is needed to optimize PDE4 inhibitor therapy for neonatal lung conditions.
Abstract:
Phosphodiesterase (PDE) inhibition has been identified in animal studies as a new treatment option for neonatal lung injury, and as potentially beneficial for early lung development and function. However, our group could show that the inhaled PDE4 inhibitor GSK256066 could have dose-dependent detrimental effects and promote lung inflammation in the premature lung. In this study, the effects of a high and a low dose of GSK256066 on lung function, structure and alveolar development were investigated. In a triple hit lamb model of Ureaplasma-induced chorioamnionitis, prematurity, and mechanical ventilation, 21 animals were treated as unventilated (NOVENT) or 24 h ventilated controls (Control), or with combined 24 h ventilation and low dose (iPDE1) or high dose (iPDE10) treatment with inhaled GSK 256066. We found that high doses of an inhaled PDE4 inhibitor impaired oxygenation during mechanical ventilation. In this group, the budding of secondary septae appeared to be decreased in the preterm lung, suggesting altered alveologenesis. Ventilation-induced structural and functional changes were only modestly ameliorated by a low dose of PDE4 inhibitor. In conclusion, our findings indicate the narrow therapeutic window of PDE4 inhibitors in the developing lung.
